Clinical Trials Directory

Trials / Sponsors / Shanghai Bovax Biotechnology Co., Ltd.

Shanghai Bovax Biotechnology Co., Ltd.

Industry · 13 registered clinical trials5 currently recruiting.

StatusTrialPhaseStarted
RecruitingTo Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Yea
HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia
Phase 22025-01-15
Active Not RecruitingA Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45
HPV Infection, HPV-Related Carcinoma, Genital Wart
Phase 12024-08-03
Active Not RecruitingA Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese M
Genital Wart, Penile Cancer, Anal Cancer
Phase 32024-07-11
TerminatedA Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Ch
Cervical Cancer, Genital Wart, CIN1
Phase 32022-12-09
CompletedEvaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Penile Cancer, Anal Cancer, PIN-1
Phase 12022-09-23
RecruitingImmune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer
2022-05-14
RecruitingImmunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer
Phase 32021-09-15
RecruitingImmunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Year
HPV Infections, Cervical Cancer, Vulvar Cancer
Phase 32021-05-28
CompletedEvaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
HPV Infections, Cervical Cancer, Vulvar Cancer
Phase 32020-09-19
CompletedEvaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Fem
Cervical Cancer, Vulvar Cancer, Vaginal Cancer
Phase 32020-05-28
RecruitingEvaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Female
Cervical Cancer, Vulvar Cancer, Vaginal Cancer
Phase 32020-04-28
CompletedEvaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Cervical Cancers, Vulvar Cancer, Vaginal Cancer
Phase 12018-10-10
CompletedA Phase I Study of Quadrivalent HPV Recombinant Vaccine
HPV Infections
Phase 12016-12-01